National Health (Pharmaceutical Benefits) Regulations (Amendment)

Overview

The Statutory Rules 1959 No. 64, Regulations under the National Health Act 1953-1958, were introduced to make amendments to the National Health (Pharmaceutical Benefits) Regulations. Enacted by the Governor-General in accordance with the advice of the Federal Executive Council, these regulations aimed to address the need for updating the list of pharmaceutical benefits and modifying certain regulations related to prescription writing and the supply of pharmaceutical benefits. The policy objective underpinning these amendments was to ensure the pharmaceutical benefits scheme remained aligned with contemporary medical needs and practices, providing Australians with access to necessary medications efficiently and effectively. The regulations came into operation on 1 August 1959 and included changes to the items covered by pharmaceutical benefits, the forms in which certain medications could be prescribed, and the exceptions to entitlement for specific pharmaceutical forms.

Scope and Application

The Regulations under the National Health Act 1953-1958, promulgated in 1959, pertain to the administration and application of pharmaceutical benefits in Australia. These regulations primarily apply to individuals and entities involved in the prescription, supply, and administration of pharmaceuticals covered under the National Health Act. The scope includes amendments to the existing National Health (Pharmaceutical Benefits) Regulations, affecting both the entities providing pharmaceutical services and the patients who benefit from them. The amendments extend to the types of pharmaceutical items eligible for subsidy, the conditions under which certain medications can be prescribed, and the forms in which these medications can be supplied. Geographically, the application of these regulations is national, as they are issued under the Commonwealth authority. However, they may also be subject to state and territory laws that complement or provide additional regulatory frameworks. Exclusions and specific limitations are noted, such as the restriction on the supply of certain oral suspension or granule forms of pharmaceutical benefits to individuals over six years of age. The regulations are designed to be implemented through subordinate instruments, allowing for further refinement and specification as necessary.

Key Provisions

The Regulations under the National Health Act 1953-1958, particularly those amending the National Health (Pharmaceutical Benefits) Regulations, bring several significant changes to the scope and administration of pharmaceutical benefits (section 2). Firstly, certain pharmaceutical items are now prescribed for specific diseases or purposes, as outlined in the updated schedules. For instance, items such as Chlorazanil, Sulfadimethoxine, and Erythrityltetranitrate have been added to the First Schedule (section 7), while specific conditions such as bronchiectasis and Turner's syndrome have been added to the list of diseases for which certain drugs can be prescribed (section 8). Additionally, the Regulations now specify that children over the age of six are not entitled to receive general pharmaceutical benefits in oral suspension or granule form, except for item 5 (section 3). The Regulations impose specific obligations on various parties, including healthcare providers and pharmaceutical suppliers. Healthcare providers must adhere to the updated list of prescribed items and ensure that they only prescribe medications for the specific conditions listed in the amended schedules (sections 2 and 8). Pharmaceutical suppliers are required to comply with the new regulations regarding the supply of specified pharmaceutical benefits, ensuring that they provide medications for the listed diseases or purposes (section 5). The Regulations also mandate that prescriptions for certain items, such as those listed in items 71 and 76, must now include these updated details (sections 4 and 6). Breaches of these Regulations can result in various legal consequences. While the specific penalties are not detailed within the text of the Regulations, under the National Health Act 1953-1958, offences related to the administration of pharmaceutical benefits can lead to substantial fines and, in some cases, imprisonment. For example, providing a pharmaceutical benefit contrary to the Regulations can result in penalties that may include fines up to a significant amount and imprisonment for a specified term, depending on the severity of the breach. Additionally, civil penalties may apply for non-compliance with the Regulations, which could further impact the entities involved.